Clinical trial · people

SS-31 (elamipretide) lowered blood HtrA2 after STEMI heart attack

Checked against the paper Clinical trialPublished by PepVault

The takeaway

In a small heart attack study, elamipretide was linked to lower levels of a blood marker the team proposes for mitochondria-driven heart cell death. It does not show effects on heart damage or recovery.

Kind
Clinical trial
Studied in
People
Published
2019
Journal
Eur Heart J Acute Cardiovasc Care

What they tested

The team asked whether blood levels of HtrA2, a protein they propose as a marker of mitochondria-driven heart cell death, rise after a STEMI heart attack and whether elamipretide lowers them.

How the study was done

A small biomarker study within the phase 2a EMBRACE trial. It included 19 patients with a first-time acute anterior STEMI (a type of heart attack) after PCI, a procedure to open the blocked artery; 10 of them got elamipretide. It also included 16 healthy donors and a mouse model in which the left anterior descending heart artery was blocked.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking SS-31? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

In people with STEMI, median blood HtrA2 was 1805.5 pg/mL, against 392.4 pg/mL in healthy donors. Patients who got elamipretide had a median of 496.5 pg/mL, a significant drop compared with the 1805.5 pg/mL STEMI level. In mice, blocking the heart artery raised plasma HtrA2 from 117.4 fg/ml to 525.2 fg/ml.

What it doesn’t show

This was a very small substudy that measured a blood marker, not heart damage or patient outcomes, and HtrA2 is not yet an established marker. The team says the results must be confirmed in a larger clinical trial.

The paper

Hortmann et al. The mitochondria-targeting peptide elamipretide diminishes circulating HtrA2 in ST-segment elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2019.

The compound

More studies on SS-31

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking SS-31? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo